Home Investors  >  Financials  >  Debt Securities

Debt Securities

Teva's senior notes and debentures and convertible debentures are issued by various special-purpose finance subsidiaries. All such debt is guaranteed by Teva Pharmaceutical Industries Ltd.

Quarterly Debt Factsheet

Senior Notes and Sustainability-Linked Senior Notes

Issued Currency Annual Interest
(%)
Principal Amount Issued
(issuance currency, in millions)
Outstanding Principal Amount
(issuance currency, in millions)
Outstanding Principal Amount
(U.S. $, in millions)
Due Prospectuses
February 2006 USD 6.150 1,000 789 789 February 2036
December 2012 USD 2.950 1,300 713 713 December 2022
March 2015 Euro 1.250 1,300 592 671 March 2023
March 2015 Euro 1.875 700 700 793 March 2027
July 2016 USD 2.800 3,000 1,454 1,454 July 2023
July 2016 USD 3.150 3,500 3,500 3,500 October 2026
July 2016 USD 4.100 2,000 2,000 2,000 October 2046
July 2016 Euro 1.125 1,500 627 710 October 2024
July 2016 Euro 1.625 750 750 849 October 2028
July 2016 CHF 0.500 350 350 383 July 2022
July 2016 CHF 1.000 350 350 383 July 2025
March 2018 Euro 3.250 700 272 308 April 2022
March 2018 Euro 4.500 900 900 1,019 March 2025
March 2018 USD 6.000 1,250 1,250 1,250 April 2024
March 2018 USD 6.750 1,250 1,250 1,250 March 2028
November 2019 Euro 6.000 1,000 1,000 1,133 January 2025
November 2019 USD 7.125 1,000 1,000 1,000 January 2025
November 2021 Euro 3.750 1,100 1,100 1,246 May 2027
November 2021 Euro 4.375 1,500 1,500 1,699 May 2030
November 2021 USD 4.750 1,000 1,000 1,000 May 2027
November 2021 USD 5.125 1,000 1,000 1,000 May 2029

Convertible Senior Debentures

Issued Currency Annual Interest
(%)
Principal Amount Issued
(issuance currency, in millions)
Outstanding Principal Amount
(issuance currency, in millions)
Outstanding Principal Amount
(U.S. $, in millions)
Due
January 2006(1) USD 0.25 575 23 23 Feb 2026

To view the prospectus supplement relating to the January 2006 debentures - click here
For conversion and other notices - click here

(1) These convertible senior debentures due 2026 include a "net share settlement" feature according to which the principal of the debentures will be paid in cash and in the case of conversion, only the residual conversion value above the principal will be paid in Teva shares.

Term Loans and Other Facilities

Source Year Currency Annual
Interest (%)

Expiration Additional Information

Revolving Credit Facility A

2019 USD USD Libor +1.75
April 2024

$1.065 b facility 

Revolving Credit Facility B

2019 USD USD Libor +1.95
April 2024 $1.15 b facility 

On April 8th 2019 Teva has entered into a new $2.3 billion revolving credit facility agreement. To view the new agreement – click here